Stockscreener 앱 받기
6.15
5.85%
0.34
시간 외 거래:
6.10
-0.05
-0.81%
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem (VSTM) Q4 Revenue Debut Highlights Ongoing Losses And Tests Bullish Profitability Timeline - simplywall.st
Verastem (VSTM) Q4 2025 Earnings Call Transcript - The Globe and Mail
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and Financial Challenges - GuruFocus
Verastem Q4 Earnings Call Highlights - MarketBeat
Verastem: Fourth Quarter Financial Results Overview - Bitget
Verastem (VSTM) Reports Strong Q4 2025 Earnings and Progress in Clinical Trials - GuruFocus
Key Developments for Verastem (VSTM) in 2026 Clinical Trials - GuruFocus
Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com India
Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks - TipRanks
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem (VSTM) Reports Strong Revenue and Advances Cancer Treat - GuruFocus
Verastem (NASDAQ:VSTM) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Verastem: Q4 Earnings Snapshot - KVUE
Verastem, Inc. releases Q4 and year end 2025 results with business update - Traders Union
Verastem (VSTM) shares updated March 4, 2026 corporate presentation - Stock Titan
Earnings Summary: Verastem Q4 - Benzinga
Verastem (NASDAQ: VSTM) grows LGSOC launch and advances KRAS G12D programs - Stock Titan
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Business Wire
Earnings Outlook For Verastem - Benzinga
VSTM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VSTM Should I Buy - Intellectia AI
Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
Will Avmapki Fakzynja Co-Pack Drive Sustainable Growth For Verastem This Year? - RTTNews
Verastem (VSTM) Projected to Post Earnings on Wednesday - MarketBeat
VSTM Technical Analysis & ETF Price Forecast - Intellectia AI
Balyasny Asset Management L.P. Increases Stake in Verastem Inc. - GuruFocus
Verastem, Inc. (VSTM) Stock Analysis: Navigating the 179% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire
What Makes Verastem (VSTM) a New Buy Stock - Yahoo Finance
RTW holds 7.84M Verastem (VSTM) shares with ownership capped at 9.99% - Stock Titan
Armistice Capital (VSTM) reports 3.54M shares, 5.30% stake - Stock Titan
Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts - MarketBeat
Verastem, Inc. (VSTM) Investor Outlook: Unveiling A Potential 184.67% Upside In Biotech - DirectorsTalk Interviews
Gap Down: What analysts say about Verastem Inc stock2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
VSTM: Strong sales, robust clinical progress, and major data updates expected mid-year - TradingView
FY2025 EPS Estimates for Verastem Increased by HC Wainwright - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Medical Facilities (OtherMFCSF), Bio-Techne (TECH) and Verastem (VSTM) - The Globe and Mail
Verastem Oncology Gains Momentum Following Drug Launch and Strategic Shift () - aktiencheck.de
Verastem, Inc. (VSTM) Stock Analysis: Exploring the 164.73% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
HC Wainwright Forecasts Verastem FY2025 Earnings - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail
Verastem Extends Cash Runway and Highlights 2025 Results - The Globe and Mail
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail
Verastem Inc (VSTM) CEO Dan Paterson Sells 970 Shares - GuruFocus
HC Wainwright Estimates Verastem FY2030 Earnings - MarketBeat
VSTM: HC Wainwright & Co. Assumes 'Buy' Rating with Price Target of $18.00 | VSTM Stock News - GuruFocus
Verastem Oncology: Preliminary Q4/2025 Revenue and Business Updates; 2026 Priorities for Novel RAS/MAPK Pathway-Driven Cancer Portfolio - marketscreener.com
Verastem Projects $17.5 Million Net Revenue for Q4 2025 - Intellectia AI
Verastem (VSTM) Makes Strides with Innovative Cancer Treatments - GuruFocus
Verastem (NASDAQ:VSTM) Now Covered by HC Wainwright - MarketBeat
3.69%
0.68%
자본화:
|
볼륨(24시간):